高级检索
当前位置: 首页 > 详情页

Predictors of Stroke Risk in Native Chinese with Nonrheumatic Atrial Fibrillation: Retrospective Investigation of Hospitalized Patients

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Peking Univ, Dept Cardiol, Peoples Hosp, Beijing 100044, Peoples R China [2]Heart Ctr Peking Tongren Hosp, Beijing, Peoples R China
出处:
ISSN:

关键词: atrial fibrillation stroke risk factor warfarin

摘要:
Background: Data on stroke risk factor profiles and atrial fibrillation (AF) for the Chinese population are sparse. This study identified risk factors for stroke among native Chinese with nonrheumatic AF. Methods: In this retrospective investigation, patients diagnosed with nonrheumatic AF were identified from 18 hospitals in representative areas of the country, from January 2000 to April 2002, based on the medical records. All parameters relevant to AF were compared between AF patients with stroke and those without. The independent risk factors for stroke were assessed with a logistic regression analysis. Results: Patients numbering 3,425 with AF were included, among whom 827 subjects were discharged on account of stroke. The prevalence of stroke in nonrheumatic AF patients was 24.15%. AF patients with stroke were significantly older than controls (73.31 +/- 9.18 versus 68.22 +/- 12.29 y, p<0.001) and more likely to have a history of hypertension (71.0 versus 51.6%, p<0.001) and diabetes (17.9 versus 11.1%, p = 0.001). Both, systolic and diastolic blood pressure, are significantly higher in patients with stroke. Of all the parameters of echocardiography, there was strong evidence that left atrial (LA) thrombi significantly increased risk of stroke. Patients with persistent AF were more likely to have stroke than paroxysmal AF patients, while lone AF is less in patients with stroke than in those without. The rate of anticoagulation treatment is only 9.27%, but there were no significant differences between the 2 groups. In multivariate analysis, age >= 75 y (odds ratio [OR] 1.76; 95% confidence interval [CI] 1.08-2.98), history of hypertension (OR 1.52; 95% CI 1.28-1.80), diabetes (OR 1.39; 95% CI 1.11-1.76), high systolic blood pressure (OR 1.71; 95% CI 1.21-2.28), LA thrombi (OR 2.77; 95% CI 1.25-6.13) were independent predictors for stroke. Conclusions: The prevalence of stroke in hospitalized nonrheumatic AF patients was high. The population-specific risk factors for stroke were age >= 75 y, diabetes, history of hypertension, high systolic blood pressure and LA thrombi by transesophageal echocardiography (TEE). These merit further evaluation.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2008]版:
大类 | 4 区 医学
小类 | 4 区 心脏和心血管系统
最新[2023]版:
大类 | 3 区 医学
小类 | 4 区 心脏和心血管系统
JCR分区:
出版当年[2007]版:
Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
最新[2023]版:
Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

影响因子: 最新[2023版] 最新五年平均 出版当年[2007版] 出版当年五年平均 出版前一年[2006版] 出版后一年[2008版]

第一作者:
第一作者机构: [1]Peking Univ, Dept Cardiol, Peoples Hosp, Beijing 100044, Peoples R China
通讯作者:
通讯机构: [1]Peking Univ, Dept Cardiol, Peoples Hosp, Beijing 100044, Peoples R China [*1]Cardiology Department ofPeople’s HospitalPeking UniversityBeijing China, 100044
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) [2]The optimal intensity of anticoagulation with warfarin in prophylaxis treatment of stroke in nonrheumatic atrial fibrillation patients in China [3]Edoxaban versus Warfarin in Patients with Atrial Fibrillation [4]Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation Systematic Review and Meta-Analysis [5]Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 [6]The Global Burden of Atrial Fibrillation and Stroke A Systematic Review of the Clinical Epidemiology of Atrial Fibrillation in Asia [7]RIVAROXABAN VS. DABIGATRAN OR WARFARIN IN REAL-WORLD OBSERVATIONAL STUDIES OF STROKE PREVENTION IN ATRIAL FIBRILLATION: SYSTEMATIC REVIEW AND META-ANALYSIS [8]Effectiveness and Safety of DOACs in Atrial Fibrillation Patients Undergoing Catheter Ablation: Results from the China Atrial Fibrillation (China-AF) Registry [9]Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves [10]Thromboembolic risks associated with paroxysmal and persistent atrial fibrillation in Asian patients: a report from the Chinese atrial fibrillation registry

资源点击量:21169 今日访问量:0 总访问量:1219 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)